[Corrigendum] The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells

• Authors:
  • Jun Fujiwara
  • Yoshihiro Sowa
  • Mano Horinaka
  • Makoto Koyama
  • Miki Wakada
  • Tsuneharu Miki
  • Toshiyuki Sakai

• View Affiliations

  
  Affiliations: Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan, Department of Urology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
• Published online on: November 25, 2015     https://doi.org/10.3892/ijo.2015.3265
• Pages: 854-854

• Copyright: © Fujiwara et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Article

The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells

JUN FUJIWARA, YOSHIHIRO SOWA, MANO HORINAKA, MAKOTO KOYAMA, MIKI WAKADA, TSUNEHARU MIKI and TOSHIYUKI SAKAI

[Related article:] Int J Oncol 40: 1483–1491, 2012; DOI: 10.3892/ijo.2012.1353

After the publication of the article, the authors noted that in Fig. 5c, the image of β-actin is incorrect. The corrected version of Fig. 5c is shown below. In Fig. 6a, the histogarms are incorrect, and the corrected Fig. 6a is shown below. In Fig. 7, the figure of PrEC is incorrect, and the corrected Fig. 7 (PrEC) is shown below. The corrected figures demonstrate the same findings as the original figures. These corrections do not alter the interpretation of the results and conclusions.

Figure 5

Figure 6

Figure 7

Figure 5

Figure 6

Figure 7